Skip to main content
Berry Genomics Co.,Ltd logo

Berry Genomics Co.,Ltd — Investor Relations & Filings

Ticker · 000710 ISIN · CNE000000PN7 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,009 across all filing types
Latest filing 2021-05-16 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 000710

About Berry Genomics Co.,Ltd

https://www.berrygenomics.com

Berry Genomics Co.,Ltd. is a biotechnology enterprise specializing in clinical genomics and genetic testing services. The company focuses on the research, development, and commercialization of genomic technologies for clinical applications. Its core portfolio includes non-invasive prenatal testing (NIPT), utilizing high-throughput sequencing to screen for chromosomal abnormalities. Beyond reproductive health, the company provides genomic solutions for oncology diagnostics, including early cancer screening and companion diagnostics, as well as testing for hereditary diseases. Berry Genomics leverages advanced sequencing platforms and proprietary bioinformatics pipelines to deliver precision medicine tools to healthcare providers and research institutions. The company is recognized for its role in the clinical application of Next-Generation Sequencing (NGS) and its extensive genomic databases used to enhance diagnostic accuracy and therapeutic outcomes.

Recent filings

Filing Released Lang Actions
关于召开2020年年度股东大会的提示性公告
AGM Information Classification · 95% confidence The document is a detailed announcement regarding the convening of the 2020 Annual General Meeting (AGM) of Chengdu Berry Genomics Co., Ltd. It includes information about the meeting date, voting procedures, agenda items to be discussed and voted on, and instructions for shareholders to participate either in person or via online voting. The document references the 2020 annual report and other related reports as agenda items but does not contain the reports themselves. The document length is 4082 characters, which is relatively short and consistent with an announcement rather than a full report. The content is focused on informing shareholders about the AGM logistics and voting process, which fits the category of AGM Information (AGM-R).
2021-05-16 Chinese
关于聘请2021年度审计机构的补充公告
Regulatory Filings Classification · 95% confidence The document is a supplementary announcement regarding the appointment of the 2021 audit firm for the company. It provides detailed information about the audit firm, its partners, their qualifications, and audit fees. The document references a previous announcement about the appointment of the audit firm and states that the appointment is subject to shareholder approval. The document is relatively short (1710 characters) and serves as an announcement or update rather than the audit report itself. It does not contain actual audit results or financial statements. Therefore, it is not an Audit Report (AR) but rather a Regulatory Filing (RNS) as it is an announcement related to audit firm appointment and supplementary information.
2021-04-29 Chinese
2021年第一季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2021 First Quarter Report" of 成都市贝瑞和康基因技术股份有限公司, indicating it is a quarterly financial report. It contains detailed financial data such as consolidated balance sheets, profit and loss statements, cash flow statements, and management discussion on financial performance and business activities for the first quarter of 2021. The length of the document (15,000 characters) and the presence of substantive financial statements and analysis confirm it is a full interim/quarterly report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2021
2021-04-28 Chinese
独立董事关于聘请公司2021年度审计机构的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent opinion from independent directors regarding the appointment of the 2021 audit firm for the company. It references regulatory rules and governance standards related to audit appointments. The content focuses on the approval and recommendation of the audit firm for the upcoming fiscal year, rather than presenting an audit report or financial statements. The document length is short (663 characters), and it does not contain financial data or audit results. Therefore, it is not an Audit Report (AR) but rather an announcement or opinion related to audit firm appointment. Given the nature and content, it fits best under Regulatory Filings (RNS) as it is a regulatory announcement about audit firm appointment and independent directors' opinion.
2021-04-28 Chinese
2020年度董事会工作报告
Management Reports Classification · 95% confidence The document is titled '2020 年度董事会工作报告' which translates to '2020 Annual Board of Directors Work Report'. It contains detailed information about the company's business development, financial status, board meetings, resolutions, governance, and future plans for the year 2020. The content includes comprehensive financial data such as net assets, revenue, and net profit, as well as detailed descriptions of board activities and governance practices. This indicates it is a management report covering the company's performance and board activities for the year, which aligns with the category 'Management Reports (MDA)'. It is not a full annual report (10-K) but a detailed management explanation of results and outlook. The document length (8203 characters) and depth of content support this classification with high confidence.
2021-04-28 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of a company, detailing the approval of various reports including the 2020 Annual Report, 2021 Q1 Report, financial statements, internal control report, audit firm appointment, profit distribution plan, and election of the Supervisory Board chairman. It references that the full reports are disclosed elsewhere and that these resolutions will be submitted to the shareholders' meeting for approval. The document itself is a meeting resolution announcement rather than the full reports. It is also relatively short (3140 characters) and mainly summarizes decisions and approvals rather than containing substantive financial data or full report content. Therefore, it fits best as a Regulatory Filing (RNS) since it is an official announcement of board resolutions and approvals without the full report content included.
2021-04-28 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.